Cell-cycle and apoptosis regulators (p16INK4A, p21 CIP1, β-catenin, survivin, and hTERT) and morphometry-defined MPECs predict metachronous cancer development in colorectal adenoma patients

Cellular Oncology

Volumn 29, Issue 4, 2007, Pages 301-313

  Soreide, Kjetil ^a   Buter, Tirza C E ^a   Janssen, Emiel A ^a   Gudlaugsson, Einar ^a   Skaland, Ivar ^a   Körner, Hartwig ^a,b   Baak, Jan P A ^a,b,c  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Adenoma; Apoptosis; Cell cycle; Colorectal; Diagnosis; Immunohistochemistry; Metachronous cancer; Molecular marker

Indexed keywords

BETA CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEIN P16INK4A; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; APOPTOSIS; ARTICLE; CANCER RISK; CANCER SIZE; CARCINOGENESIS; CELL CYCLE; CELL ELONGATION; CELL NUCLEUS; CELL STRUCTURE; COLON ADENOMA; COLON CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; TISSUE MICROARRAY;

ADENOMA; ADULT; AGED; APOPTOSIS REGULATORY PROTEINS; BETA CATENIN; CELL CYCLE PROTEINS; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DEMOGRAPHY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEOPLASMS, SECOND PRIMARY; PROPORTIONAL HAZARDS MODELS; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 34447119581     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. E. Angell-Andersen, S. Tretli, M.P. Coleman, F. Langmark and T. Grotmol, Colorectal cancer survival trends in Norway 1958-1997, Eur. J. Cancer 40 (2004), 734-742.
2. W.S. Atkin, B.C. Morson and J. Cuzick, Long-term risk of colorectal cancer after excision of rectosigmoid adenomas, N. Engl. J. Med. 326 (1992), 658-662.
3. J.P. Baak, A.J. Kruse, S.M. Garland, I. Skaland, E.A. Janssen, S. Tabrizi, S. Fagerheim, S. Robboy and S.T. Nilsen, Combined p53 and retinoblastoma protein detection identifies persistent and regressive cervical high-grade squamous intraepithelial lesions, Am. J. Surg. Pathol. 29 (2005), 1062-1066.
4. J.P. Baak, A.J. Kruse, S.J. Robboy, E.A. Janssen, B. van Diermen and I. Skaland, Dynamic behavioural interpretation of cervical intraepithelial neoplasia (CIN) by molecular biomarkers, J. Clin. Pathol. 59 (2006), 1017-1028.
5. L. Bertario, A. Russo, P. Sala, P.P. Pizzetti, G. Ballardini, S. Andreola and P. Spinelli, Predictors of metachronous colorectal neoplasms in sporadic adenoma patients, Int. J. Cancer 105 (2003), 82-87.
6. B.M. Boman, R. Walters, J.Z. Fields, A.J. Kovatich, T. Zhang, G.A. Isenberg, S.D. Goldstein and J.P. Palazzo, Colonic crypt changes during adenoma development in familial adenomatous polyposis: immunohistochemical evidence for expansion of the crypt base cell population, Am. J. Pathol. 165 (2004), 1489-1498.
7. D. Calistri, C. Rengucci, I. Seymour, E. Leonardi, M. Truini, D. Malacarne, P. Castagnola and W. Giaretti, KRAS, p53 and BRAF gene mutations and aneuploidy in sporadic colorectal cancer progression, Cell. Oncol. 28 (2006), 161-166.
8. J. De Rycke, E. Oswald, Cytolethal distending toxin (CDT): a bacterial weapon to control host cell proliferation?, FEMS Microbiol. Lett. 203 (2001), 141-148.
9. T.J. Eide, Risk of colorectal cancer in adenoma-bearing individuals within a defined population, Int. J. Cancer. 38 (1986), 173-176.
10. T. Endoh, N. Tsuji, K. Asanuma, A. Yagihashi and N. Watanabe, Survivin enhances telomerase activity via up-regulation of specificity protein 1- and c-Myc-mediated human telomerase reverse transcriptase gene transcription, Exp. Cell. Res. 305 (2005), 300-311.
11. E.R. Fearon and B. Vogelstein, A genetic model for colorectal tumorigenesis, Cell 61 (1990), 759-767.
12. M. Frattini, S. Suardi, M. Oggionni, P. Alberici, P. Radice, A. Costa, M.G. Daidone, S. Pilotti, L. Bertario and M.A. Pierotti, Different genetic features associated with colon and rectal carcinogenesis, Clin. Cancer Res. 10 (2004), 4015-4021.
13. T. Frisan, X. Cortes-Bratti and M. Thelestam, Cytolethal distending toxins and activation of DNA damage-dependent checkpoint responses, Int. J. Med. Microbiol. 291 (2002), 495-499.
14. S.Y. Fuchs, A.V. Ougolkov, V.S. Spiegelman and T.Minamoto, Oncogenic beta-catenin signaling networks in colorectal cancer, Cell Cycle 4 (2005), 1522-1539.
15. R. Gianani, E. Jarboe, D. Orlicky, M. Frost, J. Bobak, R. Lehner and K.R. Shroyer, Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa, Hum. Pathol. 32 (2001), 119-125.
16. M. Grade, H. Becker, T. Liersch, T. Ried and B.M. Ghadimi, Molecular cytogenetics: genomic imbalances in colorectal cancer and their clinical impact, Cell. Oncol. 28 (2006), 71-84.
17. S.R. Hamilton, B. Vogelstein, S. Kudo, E. Riboli, S. Nakamura, P. Hainaut, C.A. Rubio, L.H. Sobin, F. Fogt, S.J. Winawer, D.E. Goldgar and J.R. Jass, Tumours of the colon and rectum, in: World Health Organization Classification of Tumours Pathology and Genetics - Tumours of the Digestive System, S. Hamilton, L.A. Aaltonen, eds, IARC Press, Lyon, 2000, pp. 103-144.
18. D. Hanahan and R.A. Weinberg, The hallmarks of cancer, Cell 100 (2000), 57-70.
19. A.M. Haydon and J.R. Jass, Emerging pathways in colorectal-cancer development, Lancet Oncol. 3 (2002), 83-88.
20. M.P.C. Hermsen, J.P.A. Baak, M. Weiss, A. Rapallo, A. Sciutto, G. Roemen, J.W. Arends, W. Giaretti, A. De Goeij and G. Meijer, Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability, Gastroenterology 123 (2002), 1109-1119.
21. W. Heywood, B. Henderson and S.P. Nair, Cytolethal distending toxin: creating a gap in the cell cycle, J. Med. Microbiol. 54 (2005), 207-216.
22. M.M. Huycke and H.R. Gaskins, Commensal bacteria, redox stress, and colorectal cancer: mechanisms and models, Exp. Biol. Med. 229 (2004), 586-597.
23. W.M. Johnson and H. Lior, Response of Chinese hamster ovary cells to a cytolethal distending toxin (CDT) of Escherichia coli and possible misinterpretation as heat-labile (LT) enterotoxin, FEMS Microbiol. Lett. 43 (1987), 19-23.
24. O.D. Jørgensen, O. Kronborg and C. Fenger. The Funen Adenoma Follow-up Study. Incidence and death from colorectal carcinoma in an adenoma surveillance program, Scand. J. Gastroenterol. 28 (1993), 869-874.
25. T. Kanamaru, K. Tanaka, J. Kotani et al. Telomerase activity and hTERT mRNA in development and progression of adenoma to colorectal cancer, Int. J. Mol. Med. 10 (2002), 205-210.
26. G.J. Kelloff, S.M. Lippman, A.J. Dannenberg, C.C. Sigman, H.L. Pearce, B.J. Reid, E. Szabo, V.C. Jordan, M.R. Spitz, G.B. Mills, V.A. Papadimitrakopoulou, R. Lotan, B.B. Aggarwal, R.S. Bresalier, J. Kim, B. Arun, K.H. Lu, M.E. Thomas, H.E. Rhodes, M.A. Brewer, M. Follen, D.M. Shin, H.L. Parnes, J.M. Siegfried, A.A. Evans, W.J. Blot, W.H. Chow, P.L. Blount, C.C. Maley, K.K. Wang, S. Lam, J.J. Lee and S.M. Dubinett, Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - a plan to move forward, Clin. Cancer Res. 12 (2006), 3661-3697.
27. G.J. Kelloff, R.L. Schilsky, D.S. Alberts, R.W. Day, K.Z. Guyton, H.L. Pearce, J.C. Peck, R. Phillips and C.C. Sigman, Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs, Clin. Cancer Res. 10 (2004), 3908-3918.
28. P.J. Kim, J. Plescia, H. Clevers, E.R. Fearon and D.C. Altieri. Survivin and molecular pathogenesis of colorectal cancer, Lancet 362 (2003), 205-209.
29. J. Kononen, L. Bubendorf, A. Kallioniemi, M. Barlund, P. Schraml, S. Leighton, J. Torhorst, M.J. Mihatsch, G. Sauter and O.P. Kallioniemi, Tissue microarrays for high-throughput molecular profiling of tumor specimens, Nat. Med. 4 (1998), 844-847.
30. H. Körner, K. Söreide, P.J. Stokkeland and J.A. Söreide, Diagnostic accuracy of serum-carcino-embryonic antigen in recurrent colorectal cancer: A receiver operating characteristics curve analysis, Ann. Surg. Oncol. 14 (2007), 417-423.
31. H. Körner, K. Söreide, P.J. Stokkeland and J.A. Söreide, Systematic follow-up after curative surgery for colorectal cancer in Norway: a population-based audit of effectiveness, costs, and compliance, J. Gastrointest. Surg. 9 (2005), 320-328.
32. S. Kozuka, M. Nogaki, T. Ozeki and S. Masumori, Premalignancy of the mucosal polyp in the large intestine: II. Estimation of the periods required for malignant transformation of mucosal polyps, Dis. Colon Rectum 18 (1975), 494-500.
33. M. Krajewska, H. Kim, C. Kim, H. Kang, K. Welsh, S. Matsuzawa, M. Tsukamoto, R.G. Thomas, N. Assa-Munt, Z. Piao, K. Suzuki, M. Perucho, S. Krajewski and J.C. Reed, Analysis of apoptosis protein expression in early-stage colorectal cancer suggests opportunities for new prognostic biomarkers, Clin. Cancer Res. 11 (2005), 5451-5461.
34. A.J. Lax and W. Thomas, How bacteria could cause cancer: one step at a time, Trends Microbiol. 10 (2002), 293-299.
35. A.M. Lotfi, R.J. Spencer, D.M. Ilstrup and L.J. Melton, Colorectal polyps and the risk of subsequent carcinoma, Mayo Clin. Proc. 61 (1986), 337-343.
36. C.S. McArdle, R.F. McKee, I.G. Finlay et al., Improvement in survival following surgery for colorectal cancer, Br. J. Surg. 92 (2005), 1008-1013.
37. G.A. Meijer, J.P. Baak, I.C. Talbot, W.S. Atkins and G.S. Meuwissen, Predicting the risk of metachronous colorectal cancer in patients with rectosigmoid adenoma using quantitative pathological features. A case-control study, J. Pathol. 184 (1998), 63-70.
38. G.A. Meijer, J.C. Fleege and J.P. Baak, Stereological assessment of architectural changes in dysplastic epithelium of colorectal adenomas, Pathol. Res. Pract. 190 (1994), 333-341.
39. G.A. Meijer, S.G. Meuwissen, J.P. Baak, Classification of colorectal adenomas with quantitative pathology. Evaluation of morphometry, stereology, mitotic counts and syntactic structure analysis, Anal. Cell. Pathol. 9 (1995), 311-323.
40. S. Nivatvongs, Surgical management of malignant colorectal polyps, Surg. Clin. North Am. 82 (2002), 959-966.
41. J.A. O'Shaughnessy, G.J. Kelloff, G.B. Gordon, A.J. Dannenberg, W.K. Hong, C.J. Fabian, C.C. Sigman, M.M. Bertagnolli, S.P. Stratton, S. Lam, W.G. Nelson, F.L. Meyskens, D.S. Alberts, M. Follen, A.K. Rustgi, V. Papadimitrakopoulou, P.T. Scardino, A.F. Gazdar, L.W. Wattenberg, M.B. Sporn, W.A. Sakr, S.M. Lippman and D.D. Von Hoff, Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development, Clin. Cancer Res. 8 (2002), 314-346.
42. D.P. Otchy, D.F. Ransohoff, B.G. Wolff, A. Weaver, D. Ilstrup, H. Carlson and D. Rademacher, Metachronous colon cancer in persons who have had a large adenomatous polyp, Am. J. Gastroenterol. 91 (1996), 448-454.
43. J. Peat and B. Barton, Categorical and continuous variables: survival analysis, in: Medical Statistics. A Guide to Data and Critical Appraisal, J. Peat, B. Barton, eds, Blackwell Publishing Ltd, Oxford, 2005, pp. 296-305.
44. F. Radtke and H. Clevers, Self-renewal and cancer of the gut: two sides of a coin, Science 307 (2005), 1904-1909.
45. D.K. Rex, Colonoscopy: a review of its yield for cancers and adenomas by indication, Am. J. Gastroenterol. 90 (1995), 353-365.
46. J. Roose, G. Huls, M. van Beest, P. Moerer, K. van der Horn, R. Goldschmeding, T. Logtenberg and H. Clevers, Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1, Science 285 (1999), 1923-1926.
47. R.A. Sheikh, B.H. Min, S. Yasmeen, R. Teplitz, H. Tesluk, B.H. Ruebner, M. Tobi, J. Hatfield, S. Fligiel and M.J. Lawson, Correlation of Ki-67, p53, and Adnab-9 immunohistochemical staining and ploidy with clinical and histopathologic features of severely dysplastic colorectal adenomas, Dig. Dis. Sci. 48 (2003), 223-229.
48. F.A. Sinicrope, G. Roddey, M. Lemoine, S. Ruan, L.C. Stephens, M.L. Frazier, Y. Shen and W. Zhang, Loss of p21WAF1/Cip1 protein expression accompanies progression of sporadic colorectal neoplasms but not hereditary non-polyposis colorectal cancers, Clin. Cancer Res. 4 (1998), 1251-1261.
49. G.C.F. Smith, J. Beattie, M.J. Wilkie, T.J. Lightfoot, J. Coxhead, R.C. Garner and R.J. Steele, Mutations in APC, Kirstenras, and p53 - alternative genetic pathways to colorectal cancer, Proc. Natl. Acad. Sci. USA 99 (2002), 9433-9438.
50. K. Soreide, T.C. Buter, E.A. Janssen, B. van Diermen and J.P.A. Baak, A monotonous population of elongated cells (MPECs) in colorectal adenoma indicates a high risk of metachronous cancer, Am. J. Surg. Pathol. 30 (2006), 1120-1129.
51. K. Soreide, E.A. Janssen, H. Körner and J.P.A. Baak, Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis, J. Pathol. 209 (2006), 147-156.
52. K. Soreide, E.A. Janssen, H. Søiland, H. Körner and J.P.A. Baak, Microsatellite instability in colorectal cancer, Br. J. Surg. 93 (2006), 395-406.
53. S. Srivastava, M. Verma and D.E. Henson, Biomarkers for early detection of colon cancer, Clin. Cancer Res. 7 (2001), 1118-1126.
54. A. Swidsinski, M. Khilkin, D. Kerjaschki, S. Schreiber, M. Ortner, J.Weber and H. Lochs, Association between intraepithelial Escherichia coli and colorectal cancer, Gastroenterology 115 (1998), 281-286.
55. M. Thelestam and T. Frisan, Cytolethal distending toxins, Rev. Physiol. Biochem. Pharmacol. 152 (2004), 111-133.
56. J. Torhorst, C. Bucher, J. Kononen, P. Haas, M. Zuber, O.R. Kochli, F. Mross, H. Dieterich, H. Moch, M. Mihatsch, O.P. Kallioniemi and G. Sauter, Tissue microarrays for rapid linking of molecular changes to clinical endpoints, Am. J. Pathol. 159 (2001), 2249-2256.
57. M. van de Wetering, E. Sancho, C. Verweij, W. de Lau, I. Oving, A. Hurlstone, K. van der Horn, E. Batlle, D. Coudreuse, A.P. Haramis, M. Tjon-Pon-Fong, P. Moerer, M. van den Born, G. Soete, S. Pals, M. Eilers, R. Medema and H. Clevers, The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells, Cell 111 (2002), 241-250.
58. B. Vogelstein, E.R. Fearon, S.R. Hamilton, S.E. Kern, A.C. Preisinger, M. Leppert, Y. Nakamura, R. White, A.M. Smits and J.L. Bos, Genetic alterations during colorectal-tumor development, N. Engl. J. Med. 319 (1988), 525-532.
59. A.J. Watson, Apoptosis and colorectal cancer, Gut 53 (2004), 1701-1709.
60. J. Weitz, M. Koch, J. Debus, T. Hohler, P.R. Galle and M.W. Büchler, Colorectal cancer, Lancet 365 (2005), 153-165.
61. S.J. Winawer, A.G. Zauber, M.N. Ho, M.J. O'Brien, L.S. Gottlieb, S.S. Sternberg, J.D. Waye, M. Schapiro, J.H. Bond and J.F. Panish, Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup, N. Engl. J. Med. 329 (1993), 1977-1981.
62. S.J. Winawer, A.G. Zauber, M.J. O'Brien, M.N.L. Ho, Gottlieb, S.S. Sternberg, J.D. Waye, J. Bond, M. Schapiro and E.T. Stewart, Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup, N. Engl. J. Med. 328 (1993), 901-906.
63. N.A. Wong and M. Pignatelli, Beta-catenin - a linchpin in colorectal carcinogenesis?, Am. J. Pathol. 160 (2002), 389-401.
64. D. Xie, J.S. Sham, W.F. Zeng, H.L. Lin, L.H. Che, H.X. Wu, J.M. Wen, Y. Fang, L. Hu and X.Y. Guan, Heterogeneous expression and association of beta-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray, Int. J. Cancer 107 (2003), 896-902.
65. K.R. Zalata, W.A. Nasif, S.C. Ming, M. Lotfy, N.A. Nada, N.G. El-Hak and S.H. Leech, p53, Bcl-2 and C-Myc expressions in colorectal carcinoma associated with schistosomiasis in Egypt, Cell. Oncol. 27 (2005), 245-253.